Company registration number 05964690 (England and Wales)
PHARMACENTRIC LIMITED
UNAUDITED FINANCIAL STATEMENTS
FOR THE YEAR ENDED 31 OCTOBER 2025
PAGES FOR FILING WITH REGISTRAR
PHARMACENTRIC LIMITED
CONTENTS
Page
Balance sheet
1 - 2
Notes to the financial statements
3 - 7
PHARMACENTRIC LIMITED
BALANCE SHEET
AS AT
31 OCTOBER 2025
31 October 2025
- 1 -
2025
2024
Notes
£
£
£
£
Fixed assets
Intangible assets
3
685,330
745,314
Tangible assets
4
35,027
36,982
720,357
782,296
Current assets
Stocks
143,578
143,398
Debtors
5
530,515
400,433
Cash at bank and in hand
421,622
295,768
1,095,715
839,599
Creditors: amounts falling due within one year
6
(1,134,153)
(1,109,351)
Net current liabilities
(38,438)
(269,752)
Total assets less current liabilities
681,919
512,544
Creditors: amounts falling due after more than one year
7
-
0
(9,990)
Provisions for liabilities
(8,756)
(9,245)
Net assets
673,163
493,309
Capital and reserves
Called up share capital
100
100
Profit and loss reserves
673,063
493,209
Total equity
673,163
493,309
PHARMACENTRIC LIMITED
BALANCE SHEET (CONTINUED)
AS AT
31 OCTOBER 2025
31 October 2025
- 2 -

For the financial year ended 31 October 2025 the company was entitled to exemption from audit under section 477 of the Companies Act 2006 relating to small companies.

T he members have not required the company to obtain an audit of its financial statements for the year in question in accordance with section 476.

The director acknowledges his responsibilities for complying with the requirements of the Companies Act 2006 with respect to accounting records and the preparation of financial statements.

These financial statements have been prepared and delivered in accordance with the provisions applicable to companies subject to the small companies regime.

The director of the company has elected not to include a copy of the profit and loss account within the financial statements.true

The financial statements were approved and signed by the director and authorised for issue on 1 July 2026
Mr H Dodhia
Director
Company registration number 05964690 (England and Wales)
PHARMACENTRIC LIMITED
NOTES TO THE FINANCIAL STATEMENTS
FOR THE YEAR ENDED 31 OCTOBER 2025
- 3 -
1
Accounting policies
Company information

Pharmacentric Limited is a private company limited by shares incorporated in England and Wales. The registered office is Elthorne Gate, 64 High Street, Pinner, England, HA5QA.

1.1
Basis of preparation

These financial statements have been prepared in accordance with FRS 102 “The Financial Reporting Standard applicable in the UK and Republic of Ireland” (“FRS 102”) and the requirements of the Companies Act 2006 as applicable to companies subject to the small companies regime. The disclosure requirements of section 1A of FRS 102 have been applied other than where additional disclosure is required to show a true and fair view.

The financial statements are prepared in sterling, which is the functional currency of the company. Monetary a mounts in these financial statements are rounded to the nearest £.

The financial statements have been prepared under the historical cost convention, [modified to include the revaluation of freehold properties and to include investment properties and certain financial instruments at fair value]. The principal accounting policies adopted are set out below.

1.2
Going concern

A true t the time of approving the financial statements, t he director has a reasonable expectation that the company has adequate resources to continue in operational existence for the foreseeable future. Thus t he director continues to adopt the going concern basis of accounting in preparing the financial statements.

1.3
Revenue

Turnover represents revenue generated from the pharmacy and is recognised at the fair value of the consideration received or receivable for goods and services provided in the normal course of business, and is shown net of VAT and other sales related taxes. The fair value of consideration takes into account trade discount, settlement discounts and volume rebates.

The nature, timing of satisfaction of performance obligations and significant payment terms of the company's major sources of revenue are as follows:

Revenue from the sale of goods is recognised when the significant risks and rewards of ownership of the goods have passed to the buyer (usually on dispatch of the goods), the amount of revenue can be measured reliably, it is probable that the economic benefits associated with the transaction will flow to the entity and the costs incurred or to be incurred in respect of the transaction can be measured reliably.

1.4
Intangible fixed assets - goodwill

Positive goodwill is capitalised, classified as an asset on the balance sheet and amortised on a straight line basis over its useful economic life. It is reviewed for impairment at the end of the first full financial year following the acquisition and in other periods if events or changes in circumstances indicate that the carrying value may not be recoverable.

Goodwill, being the amount paid in connection with the acquisition of a business in 2008 and new acquisition of a business in 2021 and 2023 is being amortised evenly at 15 years in straight line basis.

1.5
Tangible fixed assets

Tangible fixed assets are initially measured at cost and subsequently measured at cost or valuation, net of depreciation and any impairment losses.

PHARMACENTRIC LIMITED
NOTES TO THE FINANCIAL STATEMENTS (CONTINUED)
FOR THE YEAR ENDED 31 OCTOBER 2025
1
Accounting policies
(Continued)
- 4 -

Depreciation is recognised so as to write off the cost or valuation of assets less their residual values over their useful lives on the following bases:

Leasehold land and buildings
No depreciation charge
Fixtures and fittings
20% on reducing balance

The gain or loss arising on the disposal of an asset is determined as the difference between the sale proceeds and the carrying value of the asset, and is credited or charged to profit or loss.

1.6
Stocks

Stock are valued at the lower of cost and net realisable value, after making due allowance for obsolete and slow moving items.

1.7
Taxation

The tax expense represents the sum of the tax currently payable and deferred tax.

Current tax

The tax currently payable is based on taxable profit for the year. Taxable profit differs from net profit as reported in the profit and loss account because it excludes items of income or expense that are taxable or deductible in other years and it further excludes items that are never taxable or deductible. The company’s liability for current tax is calculated using tax rates that have been enacted or substantively enacted by the reporting end date.

Deferred tax

Deferred tax liabilities are generally recognised for all timing differences and deferred tax assets are recognised to the extent that it is probable that they will be recovered against the reversal of deferred tax liabilities or other future taxable profits. Such assets and liabilities are not recognised if the timing difference arises from goodwill or from the initial recognition of other assets and liabilities in a transaction that affects neither the tax profit nor the accounting profit.

The carrying amount of deferred tax assets is reviewed at each reporting end date and reduced to the extent that it is no longer probable that sufficient taxable profits will be available to allow all or part of the asset to be recovered. Deferred tax is calculated at the tax rates that are expected to apply in the period when the liability is settled or the asset is realised. Deferred tax is charged or credited in the profit and loss account, except when it relates to items charged or credited directly to equity, in which case the deferred tax is also dealt with in equity. Deferred tax assets and liabilities are offset when the company has a legally enforceable right to offset current tax assets and liabilities and the deferred tax assets and liabilities relate to taxes levied by the same tax authority.

1.8
Retirement benefits

The company operates a defined contribution pension scheme. Contributions payable to the company's pension scheme are charged to profit or loss in the period to which they relate.

1.9
Leases
As lessor

When the company acts as a lessor, a lease is classified as a finance lease whenever it transfers substantially all the risks and rewards of ownership of the underlying asset to the lessee, either at the end of the lease term or for the major part of the economic life of the asset. All other leases are classified as operating leases. If an arrangement contains both lease and non-lease components, the company allocates the consideration in the contract to the two elements.

Rental income from operating leases is recognised on a straight line basis over the term of the relevant lease. Initial direct costs incurred in negotiating and arranging an operating lease are added to the carrying amount of the leased asset and recognised on a straight line basis over the lease term.

PHARMACENTRIC LIMITED
NOTES TO THE FINANCIAL STATEMENTS (CONTINUED)
FOR THE YEAR ENDED 31 OCTOBER 2025
1
Accounting policies
(Continued)
- 5 -
1.10
Government grants

Government grants are recognised at the fair value of the asset receive d or receivable when there is reasonable assurance that the grant conditions will be met and the grants will be received.

A grant that specifies performance conditions is recognised in income when the performance conditions are met. Where a grant does not specify performance conditions it is recognised in income when the proceeds are received or receivable. A grant received before the recognition criteria are satisfied is recognised as a liability.

2
Employees

The average monthly number of persons (including directors) employed by the company during the year was:

2025
2024
Number
Number
Total
15
15
3
Intangible fixed assets
Goodwill
£
Cost
At 1 November 2024 and 31 October 2025
1,139,758
Amortisation and impairment
At 1 November 2024
394,444
Amortisation charged for the year
59,984
At 31 October 2025
454,428
Carrying amount
At 31 October 2025
685,330
At 31 October 2024
745,314
PHARMACENTRIC LIMITED
NOTES TO THE FINANCIAL STATEMENTS (CONTINUED)
FOR THE YEAR ENDED 31 OCTOBER 2025
- 6 -
4
Tangible fixed assets
Leasehold land and buildings
Fixtures and fittings
Total
£
£
£
Cost
At 1 November 2024
2
170,788
170,790
Additions
-
0
6,802
6,802
At 31 October 2025
2
177,590
177,592
Depreciation and impairment
At 1 November 2024
-
0
133,808
133,808
Depreciation charged in the year
-
0
8,757
8,757
At 31 October 2025
-
0
142,565
142,565
Carrying amount
At 31 October 2025
2
35,025
35,027
At 31 October 2024
2
36,980
36,982
5
Debtors
2025
2024
Amounts falling due within one year:
£
£
Trade debtors
290,223
268,689
Other debtors
218,491
96,457
Prepayments and accrued income
21,801
35,287
530,515
400,433
6
Creditors: amounts falling due within one year
2025
2024
£
£
Bank loans
9,997
10,005
Trade creditors
331,661
330,838
Taxation and social security
99,009
95,403
Other creditors
693,486
673,105
1,134,153
1,109,351
PHARMACENTRIC LIMITED
NOTES TO THE FINANCIAL STATEMENTS (CONTINUED)
FOR THE YEAR ENDED 31 OCTOBER 2025
- 7 -
7
Creditors: amounts falling due after more than one year
2025
2024
Notes
£
£
Bank loans and overdrafts
8
-
0
9,990
8
Loans and overdrafts
2025
2024
£
£
Bank loans
9,997
19,995
Payable within one year
9,997
10,005
Payable after one year
-
0
9,990

9
Directors' transactions

At the year end, the company owed the director £684,084 (202 4: £662,275). The loan attracts interest and is repayable on demand.

During the year, the company paid interest of £72,000 (2024: £Nil) on the outstanding director’s loan.

2025-10-31 2024-11-01 false false false 01 July 2026 CCH Software CCH Accounts Production 2026.100 No description of principal activity Mr H Dodhia 05964690 2024-11-01 2025-10-31 05964690 2025-10-31 05964690 2024-10-31 05964690 core:NetGoodwill 2025-10-31 05964690 core:NetGoodwill 2024-10-31 05964690 core:FurnitureFittings 2025-10-31 05964690 core:LandBuildings 2024-10-31 05964690 core:FurnitureFittings 2024-10-31 05964690 core:CurrentFinancialInstruments core:WithinOneYear 2025-10-31 05964690 core:CurrentFinancialInstruments core:WithinOneYear 2024-10-31 05964690 core:Non-currentFinancialInstruments core:AfterOneYear 2025-10-31 05964690 core:Non-currentFinancialInstruments core:AfterOneYear 2024-10-31 05964690 core:CurrentFinancialInstruments 2025-10-31 05964690 core:CurrentFinancialInstruments 2024-10-31 05964690 core:ShareCapital 2025-10-31 05964690 core:ShareCapital 2024-10-31 05964690 core:RetainedEarningsAccumulatedLosses 2025-10-31 05964690 core:RetainedEarningsAccumulatedLosses 2024-10-31 05964690 bus:Director1 2024-11-01 2025-10-31 05964690 core:Goodwill 2024-11-01 2025-10-31 05964690 core:LandBuildings core:LongLeaseholdAssets 2024-11-01 2025-10-31 05964690 core:FurnitureFittings 2024-11-01 2025-10-31 05964690 2023-11-01 2024-10-31 05964690 core:NetGoodwill 2024-10-31 05964690 core:NetGoodwill 2024-11-01 2025-10-31 05964690 core:LandBuildings core:LeasedAssetsHeldAsLessee 2024-10-31 05964690 core:FurnitureFittings 2024-10-31 05964690 2024-10-31 05964690 core:LandBuildings core:LeasedAssetsHeldAsLessee 2025-10-31 05964690 core:LandBuildings core:LeasedAssetsHeldAsLessee 2024-11-01 2025-10-31 05964690 core:Non-currentFinancialInstruments 2025-10-31 05964690 core:Non-currentFinancialInstruments 2024-10-31 05964690 core:WithinOneYear 2025-10-31 05964690 core:WithinOneYear 2024-10-31 05964690 bus:PrivateLimitedCompanyLtd 2024-11-01 2025-10-31 05964690 bus:SmallCompaniesRegimeForAccounts 2024-11-01 2025-10-31 05964690 bus:FRS102 2024-11-01 2025-10-31 05964690 bus:AuditExemptWithAccountantsReport 2024-11-01 2025-10-31 05964690 bus:FullAccounts 2024-11-01 2025-10-31 xbrli:pure xbrli:shares iso4217:GBP